Enterobacterales, a family of Gram-negative bacteria inhabiting the human gut and environment, pose a significant threat to global health due to their escalating antibiotic resistance. This resistance, driven by a complex interplay of factors, renders infections caused by these bacteria increasingly difficult, if not impossible, to treat with conventional antibiotics. The mechanisms underlying this resistance are diverse and include the production of extended-spectrum β-lactamases (ESBLs), carbapenemases, and aminoglycoside-modifying enzymes, which inactivate or reduce the effectiveness of various antibiotic classes. Horizontal gene transfer, facilitated by plasmids and transposons, plays a crucial role in the rapid dissemination of resistance genes across diverse Enterobacterales species, accelerating the emergence of multidrug-resistant (MDR) and pan-drug-resistant (PDR) strains. The clinical impact of Enterobacterales antibiotic resistance is profound, leading to increased morbidity, mortality, prolonged hospital stays, and escalating healthcare costs. Infections caused by resistant Enterobacterales, such as urinary tract infections, bloodstream infections, pneumonia, and intra-abdominal infections, are associated with higher treatment failure rates and worse patient outcomes. The rise of carbapenem-resistant Enterobacterales (CRE) is particularly alarming, as carbapenems represent a last-line defense against severe infections. CRE infections often necessitate prolonged hospitalization, the use of toxic alternative therapies, and are associated with significantly increased mortality. Contributing factors to the rise in resistance include the widespread use and misuse of antibiotics in human and veterinary medicine, coupled with inadequate infection control practices in healthcare settings. The selective pressure exerted by antibiotics drives the selection and amplification of resistant strains, while poor sanitation and hygiene practices contribute to the dissemination of resistant bacteria in the community. Addressing this escalating crisis necessitates a multi-pronged approach encompassing prudent antibiotic stewardship programs, improved infection control measures, the development of novel diagnostic tools for rapid detection of resistance, and the exploration and development of new antibiotics and alternative therapeutic strategies such as phage therapy and immunotherapies. Failure to implement comprehensive strategies will result in a future where common infections become untreatable, jeopardizing global health security.